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Cyclooxygenases (COX)-1 and -2 are isoenzymes that catalyze the conversion of ara-
chidonic acid into prostaglandins (PGs). COX-2 and PGs are rapidly increased following 
seizures and are known to play important roles in the neuroinflammatory process. COX-2 
isoform has been predominantly explored as the most suitable target for pharmaco-
logical intervention in epilepsy studies, while COX-1 remains poorly investigated. In the 
present study, we evaluated the effects of selective COX-1 inhibitor or selective COX-2 
inhibitor on seizure suppression in the zebrafish pentylenetetrazole (PTZ)-seizure model. 
Zebrafish larvae were incubated in 5 μM of SC-236 for 24 h or 2.8 μM of SC-560 for 
30 min, followed by exposure to 15 mM PTZ for 60 min. Real-time quantitative PCR 
analysis was carried out to investigate transcription levels of cox1 (ptgs1), as well as to 
determine cfos levels, used as a marker for neuronal activity. Effects of selective COX-2 
or COX-1 inhibitors on locomotor activity response (velocity and distance moved) during 
PTZ exposure were evaluated using the Danio Vision video-tracking system. Our results 
showed an inducible expression of the cox1 gene after 60 min of PTZ exposure. Cox1 
mRNA levels were upregulated compared with the control group. We found that COX-2 
inhibition treatment had no effect on zebrafish PTZ-induced seizures. On the other hand, 
COX-1 inhibition significantly attenuated PTZ-induced increase of locomotor activity 
and reduced the c-fos mRNA expression. These findings suggest that COX-1 inhibition 
rather than COX-2 has positive effects on seizure suppression in the zebrafish PTZ-
seizure model.
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inTrODUcTiOn
Seizures are conceptually defined as abnormal and hypersynchronous neuronal activity that is caused 
by an imbalance between excitatory and inhibitory neurotransmission (1). Thus, it is not surprising 
that the mechanisms of action of most antiepileptic drugs (AEDs) target neuronal mechanisms 
involving in the modulation of voltage-activated ion channels, inhibition of excitatory, or enhance-
ment of inhibitory synaptic neurotransmission (2). However, approximately 30% of patients remain 
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pharmacoresistant to conventional drug-therapy (3). Therefore, 
a better understanding of the molecular mechanisms involved in 
ictogenesis and epileptogenesis is crucial for the discovery of new 
drugs with anticonvulsant properties (4–6).
There is accumulated experimental evidence supporting the 
contribution of non-neuronal cells, astrocytes, and microglia, 
to the pathophysiology of epilepsy (7–12). It is known that 
astrocytes and microglia activation promotes the release of 
proinflammatory mediators, such as interleukin-1 beta (IL-1β), 
interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), 
cyclooxygenase (COX)-2, and prostaglandins (PGs) (13, 14). 
Experimental studies suggest that proinflammatory mediators 
can affect the physiological functions of glio-neuronal com-
munications, thus contributing to neuronal hyperexcitability 
and seizure-related neuronal damage (15–17). Therefore, 
inflammatory mediators have been explored as alternative 
pharmacological targets for therapeutic intervention to treat 
epilepsy (11, 18, 19).
Cyclooxygenase-2 and PGs are rapidly increased following 
seizures and are known to play important roles in the neuroin-
flammatory process (19). Prostaglandin endoperoxide synthases 
(PTGS) or COX-1 and COX-2 are isoenzymes that catalyze the 
conversion of arachidonic acid into PGs (20). COX-1 and COX-2 
have been traditionally classified into constitutive and inducible 
expression, respectively (20). Because COX-2 is considered the 
inducible expressed isoform responsible for propagating the 
inflammatory response, several studies have been predominantly 
exploring the COX-2 isoform as the most suitable target for 
pharmacological intervention in epilepsy studies (11, 21, 22). 
However, the role of COX-2 inhibition on epileptogenesis and/or 
seizure suppression remains controversial.
Dhir et  al. (23, 24) reported that pretreatment with both, 
selective and non-selective COX-2 inhibitors in the pentylene-
tetrazole (PTZ)-kindling model in rats, decreased the behavioral 
and biochemical parameters used as kindling score. In contrast, 
Claycomb et  al. (25) reported that the pretreatment with 
rofecoxib, a selective COX-2 inhibitor, did not attenuate kindling 
progress in the PTZ-kindled mice. Recently, Katyal et  al. (26) 
showed that the selective COX-2 inhibitor, etoricoxib, presented 
an anticonvulsant effect in the PTZ-kindled rats. In addition, 
treatment with nimesulide, a COX-2 selective inhibitor, prior to 
electrical kindling, had antiepileptogenic effects in rodents (27, 
28). Furthermore, it was reported that the treatment with selec-
tive COX-2 inhibitor (SC58236) administered during the latent 
period did not modify epileptogenesis or chronic seizure activity 
after electrically induced status epilepticus (SE) in rats (29). On the 
other hand, the treatment with the SC58236 administered prior 
to electrically induced or during the chronic period increased 
seizure frequency and mortality rate (30). Proconvulsant effects 
of COX-2 inhibitor administration have also been reported in 
kainic acid-induced seizure model (31, 32). Conflicting out-
comes regarding selective COX-2 inhibition have been reported 
in the pilocarpine-induced SE model. It has been shown that the 
administration of celecoxib, a selective COX-2 inhibitor, after a 
pilocarpine-induced SE in rats had an antiepileptogenic effect 
(33). In contrast, Polascheck et al. (34) show that the selective 
COX-2 inhibitor, parecoxib, after a pilocarpine-induced SE in 
rats had no antiepileptogenic effect.
Regarding COX-1 studies in animal models of seizures/epi-
lepsy, Tanaka and colleagues reported that the selective COX-1 
inhibitor slowed the development of epilepsy in electrical amyg-
dala kindling in mouse model (35). Moreover, NSAIDs as indo-
methacin and aspirin, which inhibit the activity of both COX-1 
and COX-2, reduced seizures in the absence epilepsy model, in 
the zebrafish seizure model, and in the pilocarpine-induced SE 
model (35–37). Nonetheless, the pharmacological inhibition of 
COX-1 isoform in acute and chronic epilepsy models remains 
poorly investigated. Therefore, in the present study we evaluated 
the effects of selective COX-1 inhibitor or selective COX-2 inhibi-
tor on seizure suppression by evaluating c-fos mRNA expression 
and locomotor activity response in the zebrafish seizure model 
by evaluating the c-fos mRNA expression and locomotor activity 
response.
MaTerials anD MeThODs
animals
Wild-type adult fish were housed in 30–50 l tanks (two animals per 
liter) filled with non-chlorinated water cleared with mechanical 
and chemical filtration. Adult fish were maintained at 26 ± 2°C 
and in a simulated photoperiod cycle of 10  h dark/14  h light. 
Adult fish were fed twice a day with commercial flake fish food 
(Tetramin, Tetra, Blacksburg, VA, USA) and once a day with arte-
mia; larvae were fed with paramecium and artemia twice a day. 
Fertilized eggs were collected after natural spawning. Embryos 
and larvae were housed using Petri dishes filled with water in an 
incubator system at the same temperature and photoperiods that 
were used for maintaining the adults. All experimental protocols 
used in this study were reviewed and approved by the Ethical 
Committee for Animal Research of the University of Campinas 
(#3098-1 and #4081-1).
chemicals
5-(4-Chlorophenyl)-1-(4-methoxyphenyl)-3-trifluoromethyl 
pyrazole (SC-560), 4-[5-(4-Chlorophenyl)-3-(trifluoromethyl)-
1H-pyrazol-1-yl]-benzenesulfonamide (SC-236), and PTZ were 
purchased from Sigma-Aldrich (St. Louis, MO, USA).
Pentylenetetrazole Treatment
Detailed experimental procedures have been described previously 
(37). Briefly, 7 days post fertilization (dpf) larvae were placed in a 
24-well plate (one larva per well) containing 15 mM PTZ [seizure 
group (SG)] or PTZ-free water [control group (CG)] for 60 min. 
Following, animals were cryoanaesthetized and their heads were 
isolated, quickly frozen in liquid nitrogen, and stored at −80°C 
until further processing. A total of five samples (n = 5) were used 
for each CG and SG, and each sample was composed by pooling 
five larval heads.
FigUre 1 | evaluation of cox1 mrna expression after PTZ-induced 
seizures. Relative quantification of cyclooxygenase-1 transcript levels 
following 60 min of pentylenetetrazole (PTZ)-induced seizures in the zebrafish 
brain at 7 days post fertilization. Seizure group was exposed to 15 mM PTZ, 
and the control group was handled identically, but in PTZ-free water (n = 5 
per group). Data are presented as mean ± SEM. Statistical differences 
between control and seizure groups were tested using the Mann–Whitney 
test. Two asterisks (**) indicated that p ≤ 0.01.
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Pharmacological Pretreatment
Zebrafish larvae were incubated in 5 μM of SC-236 containing 
DMSO >0.01% or 2.8 μM of SC-560 containing >0.01% DMSO 
in Petri dishes for 24 h and 30 min, respectively. Those concentra-
tions were selected based on the study of Teraoka et al. (38). After 
the incubation, they were exposed to 15 mM PTZ for 60 min as 
described above.
real-time Quantitative Pcr
Real-time quantitative PCR (qPCR) analysis was carried out 
to investigate the transcript levels of cox1 (ptgs1) and cfos (fos), 
the last one used as a marker for neuronal activity. Total RNA 
extraction, reverse transcription, and qPCR were performed as 
previously reported (37). Briefly, total RNA was extracted from 
each group samples (control; seizure; SC-236; vehicle (DMSO)-
treated controls; and SC-560 groups) using TRIzol® (Invitrogen, 
Carlsbad, CA, USA) according to the manufacturer’s instruc-
tions, and its concentration and quality were determined with 
the Epoch™ spectrophotometer (BioTek, Winooski, VT, USA) 
and electrophoresis using agarose gels. cDNA was generated 
using the High Capacity first-strand synthesis system for RT-PCR 
(Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s 
instructions. Relative mRNA quantification was performed 
using the ABI 7500 Real-Time PCR system (Applied Biosystems, 
Foster City, CA, USA) with LuminoCt® qPCR ReadyMix (Sigma-
Aldrich, St. Louis, MO, USA) and TaqMan® Gene Expression 
Assay (Invitrogen, Carlsbad, CA, USA). Runs were carried out 
in triplicate using the housekeeping gene eef1a1l1 (Dr03432748_
m1) to normalize the mRNA level of ptgs1 (Dr03087197_m1) and 
c-fos (fos) (Dr03100809_g1). Data were analyzed using the SDS 
7500 software (Applied Biosystems) to estimate qPCR efficiency 
and quantify the relative gene expression. A total of five samples 
(n = 5) were used for each group and each sample comprising a 
pool of five larval heads.
Behavioral seizure locomotor activity
At 7 dpf, zebrafish larvae were transferred to 96-well plate in a 
semi-randomized distribution (in order to have larvae distrib-
uted in lines and columns along the plate) using a micropipette 
in a volume of 50 μl and acclimated for 30 min to minimize any 
interference in the test. Following acclimation, 50 μl of aquarium 
water or 50 μl of a 30 mM PTZ solution (dissolved in aquarium 
water) was added to obtain final volume and concentration of 
15  mM. After that, the locomotor activity for each larva was 
recorded during 30  min using an automated computerized 
video-tracking system DanioVision (Noldus, Wageningen, The 
Netherlands). A total of seven zebrafish larvae (n  =  7) were 
used to compose each experimental group: (i) control, (ii) sei-
zure, (iii) vehicle (DMSO)-treated controls, (iv) SC-236, or (v) 
SC-560 PTZ-treated groups. The total distance moved and the 
speed (velocity) for each larva from each group was quantified 
using the EthoVision XT locomotion tracking software (Noldus, 
Wageningen, The Netherlands).
statistical analysis
Data are presented as mean values ±  SEM. Statistical analysis 
was performed using the GraphPad Prism version 5.0 (GraphPad 
Software, San Diego, CA, USA). In all the analyses, the significance 
level was set at p ≤  0.05. Statistical comparisons between two 
groups were performed using the Mann–Whitney test. Statistical 
comparisons between more than three groups were assessed by 
one-way analysis of variance (ANOVA) followed by Bonferroni’s 
post hoc test.
resUlTs
evaluation of cox1 mrna expression after 
PTZ-induced seizures
We previously reported that cox2b mRNA expression was 
upregulated after PTZ-induced seizures in 7 dpf zebrafish larva 
(37). To determine whether the cox1 transcription is affected fol-
lowing PTZ-induced seizure, we used real-time qPCR to measure 
the relative quantification of the cox1 gene. Our results showed 
an inducible expression of cox1 after 60 min of PTZ exposure. 
Cox1 mRNA levels were upregulated compared with the control 
group (p = 0.004; Figure 1). The mean ± SEM of control and PTZ 
groups were 1.1 ± 0.07 and 1.5 ± 0.07, respectively.
effects of selective cOX-1 or cOX-2 
inhibitors on c-fos mrna expression
We previously showed that the treatment with indomethacin, 
a non-selective COX-1 and COX-2 inhibitor, prior to PTZ-
induced seizures suppresses the c-fos mRNA upregulation (37). 
Here, we sought to address the contribution of either a COX-1 
or COX-2 inhibition on c-fos mRNA expression. Pretreatment 
with the selective COX-1 inhibitor, SC-560 (2.8 μM), significantly 
decreased the c-fos mRNA expression compared to PTZ group 
FigUre 3 | effect of selective cOX-2 inhibitor (sc-236) on c-fos 
mrna expression. Relative quantification of c-fos transcript levels 
immediately after pentylenetetrazole (PTZ)-induced seizures in zebrafish brain 
at 7 days post fertilization. Seizure group (SG) was composed of animals 
exposed to 15 mM PTZ for 60 min. The SC-236 group (5 μM) was 
composed of animals that received SC-236 treatment prior to PTZ exposure. 
Animals in the control group (CG) were handled identically but included 
exposure to water [no PTZ, DMSO (>0.01%), or SC-560 treatments; n = 5 
per group]. Data are presented as mean ± SEM. One-way ANOVA followed 
by Bonferroni’s post hoc test was performed to determine statically 
significant differences between groups. Three asterisks (***) indicated that 
that p ≤ 0.001.
FigUre 2 | effect of selective cOX-1 inhibitor (sc-560) on c-fos 
mrna expression. Seizure group (SG) was composed of animals exposed 
to 15 mM PTZ for 60 min. The SC-560 group (2.8 μM) was composed of 
animals that received SC-560 treatment for 30 min prior to PTZ exposure. 
Animals of the control group (CG) were handled identically but included 
exposure to water [no PTZ, DMSO (>0.01%), or SC-560 treatments; n = 5 
per group]. Data are presented as mean ± SEM. One-way ANOVA followed 
by Bonferroni’s post hoc test was performed to determine statically 
significant differences between groups. Three asterisks (***) indicated that 
that p ≤ 0.001.
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(Figure 2). The mean ±  SEM obtained were (i) control group: 
0.82 ±  0.08; (ii) seizure group (PTZ): 57.4 ±  1.77; (iii) vehicle 
(DMSO)-treated control (>0.01%) group: 0.57 ± 0.09; and (iv) 
SC-560 group: 27.72  ±  1.9 (Figure  2). However, our results 
showed that the selective COX-2 inhibitor, SC-236, treatment had 
no effect on c-fos mRNA expression (Figure 3). The mRNA levels 
of SC-236 group were similar with those found in the PTZ group 
(Figure 3). The mean ±  SEM obtained were (i) control group: 
0.82 ±  0.08; (ii) seizure group (PTZ): 57.4 ±  1.77; (iii) vehicle 
(DMSO)-treated control (>0.01%) group: 0.57 ± 0.05; and (iv) 
SC-236 group: 59.16 ± 2.9.
effects of selective cOX-1 or cOX-2 
inhibitors on locomotor activity response 
during PTZ exposure
Our initial pilot experiment revealed that after 1  h of PTZ 
exposure there was no difference in velocity and distance 
moved between PTZ and the control groups. As pointed out 
by Afrikanova et al. (39), the decline of the locomotor activity 
observed in longer periods of PTZ exposure might be due to 
the fact that the larvae begin to undergo seizures with more 
frequency and spending more time on seizure stage III (loss 
of posture), which, as consequence, promotes a decrease of 
the locomotor activity. Therefore, we choose to evaluate the 
locomotor activity during 30 min of PTZ exposure. Our results 
have shown that SC-560 treatment inhibits the PTZ-induced 
increase of locomotor activity (Figure  4). The velocity and 
distance moved of the SC-560 group were lower in comparison 
to the PTZ group (Figures 4A,B). For velocity, the mean ± SEM 
of the control, seizure (PTZ), vehicle (DMSO)-treated control 
(>0.01%), and SC-560 groups were, respectively, 1.4  ±  0.16, 
2.96 ± 0.20, 1.35 ± 0.26, and 1.55 ± 0.20. For distance moved, the 
mean ± SEM of control, seizure (PTZ), vehicle (DMSO)-treated 
control (>0.01%), and SC-560 were, respectively, 2536 ± 297.7, 
5311 ±  342.5, 2432 ±  460.6, and 2802 ±  360.7. On the other 
hand, SC-236 treatment did not reduce PTZ-induced increase of 
locomotor activity (Figures 5A,B). Velocity and distance moved 
of the SC-236 group were similar to those found to the PTZ 
group (Figures 5A,B). For velocity, the mean ± SEM of control, 
seizure (PTZ), vehicle (DMSO)-treated control (>0.01%), and 
SC-236 were, respectively, 1.3 ± 0.16, 1.26 ± 0.18, 2.22 ± 0.22, 
and 2.20 ± 0.14. For distance moved, the mean ± SEM of control, 
seizure (PTZ), vehicle (DMSO)-treated control (>0.01%), and 
SC-236 groups were, respectively, 2365 ± 285.6, 2258 ± 322.9, 
3995 ± 403.0, and 3965 ± 257.0.
DiscUssiOn
In the central nervous system (CNS), both COX-1 and COX-2 
are constitutively expressed in neurons, astrocytes, and 
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FigUre 4 | effect of the selective cOX-1 inhibitor on locomotor activity response during PTZ exposure. (a) Velocity and (B) distance moved. Animals 
were exposed to 2.8 μM of SC-560 for 30 min prior to pentylenetetrazole (15 mM) exposure. Animals in the control group (CG) were handled identically but included 
exposure to water [no PTZ, DMSO (>0.01%), or SC-560 treatments; n = 7 per group]. At 7 days post fertilization, larval zebrafish were transferred to 96-well plate 
and acclimated for 30 min to minimize any disturbance related to handling and transport from the Petri dishes to 96-well plate. Following acclimation, locomotor 
activity for each treatment group was recorded for 30 min using an automated video-tracking system Danio Vision (Noldus, Wageningen, The Netherlands). The 
distance moved and the velocity for each larva from each group was performed using EthoVision XT locomotion tracking software (Noldus, Wageningen, The 
Netherlands). Data are presented as mean ± SEM. One-way ANOVA followed by Bonferroni’s post hoc test was performed to determine statically significant 
differences between groups. Three asterisks (***) indicated that that p ≤ 0.001.
FigUre 5 | effect of selective cOX-2 inhibitor (sc-236) on locomotor activity response during PTZ exposure. (a) Velocity and (B) distance moved. 
Animals were exposed to 5 μM of SC-236 for 24 h prior to pentylenetetrazole (15 mM) exposure. Animals in the control group (CG) were handled identically but 
included exposure to water [no PTZ, DMSO (>0.01%), or SC-236 treatments; n = 7 per group]. At 7 days post fertilization, larval zebrafish were transferred to a 
96-well plate and acclimated for 30 min to minimize any disturbance related to handling and transport from the Petri dishes to the plate. Following acclimation, 
locomotor activity for each treatment group was recorded for 30 min using an automated video-tracking system Danio Vision (Noldus, Wageningen, The 
Netherlands). The distance moved and the velocity for each larva from each group was performed using EthoVision XT locomotion tracking software (Noldus, 
Wageningen, The Netherlands). Data are presented as mean ± SEM. One-way ANOVA followed by Bonferroni’s post hoc test was performed to determine statically 
significant differences between groups. One asterisk (*) indicated that p ≤ 0.05; two asterisks (**) indicated that p ≤ 0.01.
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microglial cells, and both COXs lead to PG productions, which 
are important inflammatory mediators (20). Experimental 
evidence has shown that PGs are markedly increased following 
seizures and may contribute to epileptogenesis and reduction 
in the seizure threshold (11, 17–19). Traditionally, COX-1 and 
COX-2 isoforms have been considered constitutive and inducible 
expression, respectively (40–42). Therefore, most experimental 
epilepsy research reports have focused on the COX-2 isoform 
because of its role in the inflammatory response through PGs 
production (18, 19). Several studies were designed to interfere 
with the COX-2 enzyme without affecting the homeostatic func-
tion of COX-1, by using selective COX-2 inhibitors. However, 
both proconvulsant and anticonvulsant effects of COX-2 inhibi-
tion have been reported, and their role still remains controversial 
(11, 19, 20).
It has been reported that the therapeutic outcome of COX-2 
inhibition on epileptogenesis and/or seizure suppression 
appears to depend on many factors including the type of inhibi-
tor used (non-selective or selective) and the timing of the treat-
ment administration (prior or after to seizure onset) (11, 36). 
Moreover, comparisons between these conflicting reports are 
difficult to be interpreted because they used different methods 
for seizure-induction, were evaluated in mature or immature 
brain, were assessed in different phase of epileptogenesis as well 
as were performed in different species (11, 36). Nonetheless, 
studies using non-selective COX inhibitors in the zebrafish 
seizure model or in the absence epilepsy rodent model as well 
as following pilocarpine-induced SE, showed anticonvulsant 
effects (35–37). Thus, these data indirectly suggest the involve-
ment of the COX-1 isoform on seizure inhibition in these 
models.
Notably, experimental studies have reported neuroprotective 
effects of selective COX-1 inhibition and NSAIDs, with higher 
selectivity for COX-1, in models of neurodegenerative diseases 
such as Alzheimer disease and traumatic brain injury (41–49). 
It is noteworthy, however, that continuous NSAIDs use is associ-
ated with gastrointestinal side effects due to COX-1-derived 
PGs inhibition (42, 50). On the other hand, the continuous use 
of selective COX-2 inhibitors (coxibs) has been associated with 
increased risk of cardiovascular side effects (42, 50). Therefore, 
the benefit–risk evaluation of the administration of selective or 
non-selective COX inhibitors, as for many other drugs, should 
be considered.
Although several studies have suggested that COX-1 might 
have an important role in the neuroinflammation of neurode-
generative diseases (40–42), only few studies have investigated 
the association between COX-1 and epilepsy (35, 36). Notably, 
COX-1 expression has increased following kindling progres-
sion and in the SE induced by pilocarpine (35, 36). Moreover, 
treatment with selective COX-1 inhibitor reduced the epilep-
togenesis in the electrical kindling model (35). Based on this 
background, we sought to investigate the contribution of each 
COX isoforms on seizure suppression in the zebrafish PTZ-
seizure model.
Although it is considered as an acute seizure model, the 
zebrafish is a powerful model in neuroscience research since it 
has many advantages when performing imaging studies, genetic 
manipulation, and modeling different disease mechanisms. In 
addition, it is a convenient model for drug screening, making it 
suitable for translational studies in epilepsy (51–53).
The zebrafish has homologs for both COX-1 and COX-2 
human genes named cox1 (ptgs1) and cox2 (ptgs2), respectively 
(54). Furthermore, the zebrafish PTZ-seizure model has been 
widely used as an in  vivo high-throughput screening method 
for antiepileptic drug discovery (55–57). Screening of new 
compounds with anticonvulsants’ properties is performed by 
evaluating the inhibition of the seizure-like behavior (i.e., by 
assessing the locomotor activity), as well as by the suppression of 
the increased neuronal activity, through the c-fos quantification in 
the brain and/or by the inhibition of epileptiform electrographic 
activity (39, 55, 58).
In this study, we showed that the cox1 mRNA expression was 
increased after PTZ-induced seizure (Figure 1). In addition, we 
found that the selective COX-1 inhibitor, SC-560, significantly 
decreased the c-fos mRNA expression (Figure 2) and inhibited 
the PTZ-induced increase of locomotor activity (Figure  4). 
Taking all together, these findings suggest that COX-1 inhibition 
has an important role on seizure suppression in the zebrafish sei-
zure model, whereas the selective COX-2 inhibitor (SC-236) had 
no effect, producing any changes in the c-fos mRNA expression 
(Figure 3) and locomotor activity (Figure 5).
Our findings suggest that inhibition of the COX-1 isoform has 
an important role on seizure suppression in the zebrafish PTZ-
seizure model. Together, with the accumulating knowledge aris-
ing from other animal models of epilepsy and given the emerging 
importance of the zebrafish as a model for epilepsy investigations 
and drug screening, we believe these findings may contribute 
with new avenues of investigations toward seizure suppression.
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